Marina Zakharova

Dr. Marina Zakharova

orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 January 2005 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
ESEkaterina Semenova
Ekaterina Semenova
LMLeonid Minakhin
Leonid Minakhin
EBEkaterina Bogdanova
Ekaterina Bogdanova
MNMaxim Nagornykh
Maxim Nagornykh
AVAnatoliy Vasilov
Anatoliy Vasilov
KSKonstantin Severinov
Konstantin Severinov
When a plasmid containing restriction–modification (R–M) genes enters a naïve host, unmodified host DNA can be destroyed by restriction endonuclease. Therefore, expression of R–M genes must be regulated to ensure that enough methyltransferase is produced and that host DNA is methylated before the endonuclease synthesis begins. In several R–M systems, specialized Control (C) proteins coordinate expression of the R and the M genes. C proteins bind to DNA sequences called C-boxes and activate expression of their cognate R genes and inhibit the M gene expression, however the mechanisms remain undefined. Here, we studied the regulation of gene expression in the C protein-dependent EcoRV system. We map the divergent EcoRV M and R gene promoters and we define the site of C protein-binding that is sufficient for activation of the EcoRV R transcription.

3 January 2017 in AMB Express
Verified
Journal Article
Open access
PDF file
ALAlexander Lisov
Alexander Lisov
OBOksana V. Belova
Oksana V. Belova
ZLZoya A. Lisova
Zoya A. Lisova
NVNataliy G. Vinokurova
Nataliy G. Vinokurova
ANAlexey Nagel
Alexey Nagel
ALAlexey A. Leontievsky
Alexey A. Leontievsky
Four xylanases of Cellulomonas flavigena were cloned, expressed in Escherichia coli and purified. Three enzymes (CFXyl1, CFXyl2, and CFXyl4) were from the GH10 family, while CFXyl3 was from the GH11 family. The enzymes possessed moderate temperature stability and a neutral pH optimum. The enzymes were more stable at alkaline pH values. CFXyl1 and CFXyl2 hydrolyzed xylan to form xylobiose, xylotriose, xylohexaose, xylopentaose, and xylose, which is typical for GH10. CFXyl3 (GH11) and CFXyl4 (GH10) formed the same xylooligosaccharides, but xylose was formed in small amounts. The xylanases made efficient saccharification of rye, wheat and oat, common components of animal feed, which indicates their high biotechnological potential.

9 February 2011 in Nucleic Acids Research
Verified
Journal Article
Open access
MNMaxim Nagornykh
Maxim Nagornykh
MZMarina Zakharova
Marina Zakharova
APAlexey Protsenko
Alexey Protsenko
EBEkaterina Bogdanova
Ekaterina Bogdanova
ASAlexander Solonin
Alexander Solonin
KSKonstantin Severinov
Konstantin Severinov
The Eco29kI restriction-modification (R-M) system consists of two partially overlapping genes, eco29kIR, encoding a restriction endonuclease and eco29kIM, encoding methyltransferase. The two genes are thought to form an operon with the eco29kIR gene preceding the eco29kIM gene. Such an organization is expected to complicate establishment of plasmids containing this R-M system in naive hosts, since common logic dictates that methyltransferase should be synthesized first to protect the DNA from cleavage by the endonuclease. Here, we characterize the Eco29kI gene transcription. We show that a separate promoter located within the eco29kIR gene is sufficient to synthesize enough methyltransferase to completely modify host DNA. We further show that transcription from two intragenic antisense promoters strongly decreases the levels of eco29kIR gene transcripts. The antisense transcripts act by preventing translation initiation from the bicistronic eco29kIR-eco29kIM mRNA and causing its degradation. Both eco29kIM and antisense promoters are necessary for Eco29kI genes establishment and/or stable maintenance, indicating that they jointly contribute to coordinated expression of Eco29kI genes.

1 January 2021 in Sign: problematic field in mediaeducation
Verified
Journal Article
Closed access
MZMarina Zakharova
Marina Zakharova
В статье анализируется существующий опыт построения коммуникаций бренда с потребителями в сети интернет. Рассматриваются основные виды пользовательского контента, и выделяются его особенности и преимущества. Представлены результаты нескольких глобальных исследований потребительского поведения в цифровой среде. Показывается, как формируется лояльность на основе применения пользовательского контента, и как этот контент может быть использован в коммуникациях с...

11 July 2025 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
SMSergey Markin
Sergey Markin
SISergei Ivanov
Sergei Ivanov
IBIgor P. Beletsky
Igor P. Beletsky
MZMarina Zakharova
Marina Zakharova
EPE. A. Ponomarev
E. A. Ponomarev
EAE. V. Arzamascev
E. V. Arzamascev
The aim. To study possible allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase molecule with the amino acids replacement Lys74, Glu75 and Arg77 with alanine in preclinical and clinical studies.Materials and methods. The allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase drug were studied using standard methods in accordance with the Guidelines for the Preclinical Study of New Substances in guinea pigs (n=15) and mice (n=45) at doses 5, 10 and 20 times higher than therapeutic (for humans). A clinical study was conducted in 100 patients with acute ST-segment elevation myocardial infarction after a single intravenous injection of the drug. The study included the determination of titers of specific antibodies to recombinant non-immunogenic staphylokinase and the study of plasma neutralizing activity.Results. During the complete set of preclinical studies, it was found that the drug does not affect the cellular and humoral immune response in guinea pigs and mice at doses many times higher than therapeutic doses for humans. It was found that the drug did not cause an immediate-type of hypersensitivity reaction (Weigle index 0) and a delayed type IV (0 points according to S.V. Suvorov) in guinea pigs, did not affect the cellular capacity of popliteal lymph nodes (reaction index 0.91), did not affect the number of nucleated and antibody-forming cells in the spleen of mice. As a result of a clinical study of recombinant non-immunogenic staphylokinase, no allergic reactions were registered. Assessment of the neutralizing activity of the plasma of patients who were administered recombinant non-immunogenic staphylokinase showed that 70% samples did not have neutralizing activity: 30% of the patients’ samples were characterized by a minimum neutralizing activity of 0.33±0.02 μg/mL, which is 30–310 times lower than after the use of native staphylokinase. These values are 7.8 times lower than the determined concentration of recombinant non-immunogenic staphylokinase in the blood (2.59 μg/mL). Thus, the drug does not lead to the anti-staphylokinase neutralizing antibodies formation capable to neutralize its effect upon repeated administration.Conclusion. According to the results of the trials, the absence of allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase and its safety in relation to the immune system have been proven.

29 September 2025 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
SISergei Ivanov
Sergei Ivanov
IBIgor P. Beletsky
Igor P. Beletsky
MZMarina Zakharova
Marina Zakharova
EPE. A. Ponomarev
E. A. Ponomarev
ZCZh. Yu. Chefranova
Zh. Yu. Chefranova
SMSergey Markin
Sergey Markin
The aim. To investigate the pharmacokinetic parameters of non-immunogenic staphylokinase (Fortelyzin®, SuperGene LLC, Russia) in patients with acute myocardial infarction with ST-segment elevation (STEMI) on the electrocardiogram and in patients with ischemic stroke.Materials and methods. The clinical study was conducted in 50 patients with STEMI after a single intravenous administration of non-immunogenic staphylokinase at a dose of 15 mg and in 50 patients with ischemic stroke after a single intravenous administration of the drug at a dose of 10 mg. The main pharmacokinetic parameters were determined: half-life, initial concentration, volume of distribution, clearance, and area under the pharmacokinetic curve.Results. As a result of the study of the pharmacokinetics of non-immunogenic staphylokinase, it was found that after a single intravenous administration of the drug at a dose of 15 mg, the initial concentration was 7.1 ± 2.7 μg/mL, the half-life was 5.77 ± 0.72 min, the clearance was 0.33 ± 0.04 l/min, and the area under the pharmacokinetic curve (AUC0-t) was 42.9 ± 3.2 μg/mL*min. After administration of the drug at a dose of 10 mg, the initial concentration was 2.8 ± 0.3 μg/ml, the half-life was 5.11 ± 0.56 min, the clearance was 0.35 ± 0.06 l/min, and the area under the pharmacokinetic curve (AUC0-t) was 28.5 ± 3.6 μg/mL*min. The terminal half-life was 32 min in both dosage regimens.Conclusion. It was found that non-immunogenic staphylokinase is characterized by a short half-life and high clearance, which ensures the safety of the drug in clinical practice. The peculiarities of the pharmacodynamics of non-immunogenic staphylokinase, associated with its interaction with plasmin in the thrombus and subsequent recirculation of released drug molecules, allow it to be used in low doses, regardless of the patient’s body weight, despite the short half-life.